Crossmark

Venlafaxine XR treatment for older patients with major depressive disorder: decision trees for when to change treatment

Crossref DOI link: https://doi.org/10.1136/ebmental-2022-300479

Published Online: 2022-09-13

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Kim, Helena Kyunghee https://orcid.org/0000-0002-6578-2109
Blumberger, Daniel M

Karp, Jordan F

Lenze, Eric

Reynolds, Charles F

Mulsant, Benoit H
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct00892047 at ClinicalTrials.gov

Documents that mention this clinical trial

Venlafaxine XR treatment for older patients with major depressive disorder: decision trees for when to change treatment
https://doi.org/10.1136/ebmental-2022-300479

Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial
https://doi.org/10.1016/s0140-6736(15)00308-6
Funding

Funding for this research was provided by:

National Center for Advancing Translational Sciences (UL1 TR000448)

Campbell Family Mental Health Research Institute (Not applicable)

Taylor Family Institute for Innovative Psychiatric Research (Not applicable)

University of Pittsburgh Medical Center (Not applicable)

National Institute of Mental Health (P30 MH90333)

National Institute of Mental Health (R01 MH083643)

National Institute of Mental Health (R01 MH083648)

National Institute of Mental Health (R01 MH083660)